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ABSTRACT 
 
In the continuous search for earlier diagnosis and improved therapeutic modalities against cancer, based on our 
constantly increasing knowledge of cancer biology, aptamers hold the promise to expand on current antibody 
success, but overcoming some of the problems faced with antibodies as therapeutic or delivery agents in cancer. 
However, as the first aptamer reached the market as an inhibitor against angiogenesis for the treatment of macular 
degeneration, aptamers have found only limited applications or interest in oncology, and even less as 
radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of tumours. Yet, the chemistry for the 
labelling of aptamers and the options to alter their pharmacokinetic properties, to make them suitable for use as 
radiopharmaceuticals is now available and recent advances in their development can demonstrate that these 
molecules would make them ideal delivery vehicles for the development of targeted radiopharmaceuticals that could 
deliver their radiation load with accuracy to the tumour site, offering improved therapeutic properties and reduced 
side effects. 
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INTRODUCTION 
 
Our knowledge on cancer has changed 
dramatically over the last few years and, with it, 
our approach to diagnosis and therapy. A lot has 
become known about the causes, onset and spread 
of the disease, the different features of individual 
cancers and their origin. Scientific knowledge and 
technological development are constantly 
improving the outlook on cancer. Yet, even though 
prevention methods, through changes in lifestyle, 
vaccinations etc. can significantly reduce the 
cancer incidence, there are still going to be 
cancers, caused by various factors, even if these 
are spontaneous mutations. Thus, there is clearly a 
need for improved therapeutic approaches to make 
these cancers treatable conditions, instead of life-
threatening or debilitating diseases. There is, thus, 
a continuous effort to develop novel therapeutic 
approaches, based on surgical improvements and 
novel chemotherapeutic or radiotherapeutic 
approaches. These may attempt to improve on 
previous molecules or techniques, find new ways 
to target previous targets, deliver radiation more 
specifically and use different kinds of radiation 
with improved properties, or generate novel agents 
that are targeting new markers identified from 
large proteomics efforts (Missailidis, 2008).  
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When chemotherapy first became established, 
there were predictions that, within a few years, 
radiotherapy would be a thing of the past. Yet, 
radiotherapy remains a very successful treatment, 
both radical and palliative, and is indicated in over 
50% of all cancer cases. Improvements to existing 
techniques, and development of new ones, are 
happening at a rapid rate. One of the progress 
areas in radiotherapy is the use of 
radiopharmaceuticals and molecular targeted 
radiotherapy approaches to deliver radiation 
specifically to the cancer site, improving clinical 
outcome and reducing side effects.  
Radiopharmaceuticals have traditionally only been 
used when there is a high uptake by a particular 
part of the body, such as Iodine-131 by the 
thyroid. Otherwise, the use of a radiopharma-
ceutical would be dangerous, often causing more 
damaging than therapeutic effect. So, the majority 
of radiotherapy approaches are focused on external 
beam therapy, which is now quite accurate. 
However, research on new ways of targeting 
cancers with radiopharmaceuticals is likely to 
result in the wider use of unsealed source 
radiotherapy, with the possibility that treatment 
may be individually tailored to the patient’s 
cancer. Such molecular targeted radiotherapy 
approaches are evolving into using targeted 
therapeutics to deliver radiotherapy specifically to 
the tumour site, where a seed can not be 
introduced. With the use of appropriate targeting 
agents, such as antibodies and aptamers, a new 
generation of targeted radiopharmaceuticals has 
emerged, with conjugated antibodies already in the 
market, such as Zevalin, and others in clinical 
development. Aptamers used as delivery agents for 
radiotherapy are currently at preclinical stage 
(Borbas et al., 2007). The development of 
coupling techniques to such delivery agents led to 
the use of new chelators and different metals that 
could emit alpha or beta particles for cancer 
radiotherapy and can now be directed specifically 
at the tumour site. 
It is not surprising that the above developments in 
molecular radiotherapy came at a time when the 
biggest boom in anticancer therapeutics has been 
in the area of biological medicines. Antibodies and 
nucleic acid therapeutics have been obtaining FDA 
approval faster than ever before, and dozens of 
these reagents are now in clinical trials. Antibodies 
are the most well-established biological agents, 
with more than 40 monoclonal antibodies 
currently in clinical trials against various forms of 
cancer (Belimezi, 2008). Similarly, various classes 
of nucleic-acid therapeutics, including aptamers, 
antisense, antigene and siRNA agents, are also 
being developed as tumour-specific therapies.  
Aptamers are oligonucleotides with a defined 
conformation that allows them to bind specifically 
to target molecules, including proteins, peptides, 
enzymes, antibodies and cell surface receptors 
(Bacher and Ellington, 1998). Aptamers vary in 
size between 25 and 50 bases and are identified 
from combinatorial libraries through selective 
targeting and affinity maturation. They offer 
unique benefits compared to other targeting 
agents, in that they bind with high affinity and 
selectivity, are easily and quickly synthesised 
using in vitro techniques, are stable and consistent 
(Jayasena, 1999), making them alternatives to 
antibodies and peptides for diagnostic assays 
(Hesselberth et al., 2000; Ferreira et al., 2008). As 
aptamers are not immunogenic or toxic, they also 
have potential as therapeutic and imaging agents 
(Borbas et al., 2007). Aptamers have been 
primarily used for their ability to act as inhibitors 
by binding to specific receptors, thus blocking a 
cellular pathway, which has led to clinical trials of 
aptamers for the treatment of cancer and macular 
degeneration and the first FDA approval for an 
aptamer against AMD, named Pegaptanib. The 
two year safety results demonstrated that all the 
doses of Pegaptanib were well tolerated and any 
adverse events were momentary owing to the 
injection preparation and procedures rather than 
the Pegaptanib drug (D’Amico et al., 2006). 
Furthermore, labelled aptamers have been used as 
antibody mimics in sandwich assays, ELISAs, and 
Western blots (Bacher and Ellington, 1998; 
Jayasena, 1999; Morris et al., 1998; Ferreira et al., 
2008), and their ability to directly transduce 
molecular recognition into optical signals. The 
demonstration that aptamers, either through 
incorporation of fluorescent bases in the selection 
process (Jhaveri et al., 2000) or through post-
SELEX modifications to generate aptamer beacons 
(Potyrailo et al., 1998), can be used for ligand 
identification based on detectable changes in the 
fluorescence emission upon ligand binding 
indicates their potential as a sensitive detection 
tool. However, aptamers have not yet reached their 
full potential, partly because their labelling has not 
been fully explored, particularly with regards to 
radio- and MRI labelling that would allow them 
specific delivery of radiotherapy, with minimised 
side effects and could significantly increase 
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definition in gamma-camera or MRI imaging, by 
carrying radionuclides or contrast agents 
respectively, specifically at the disease site.  
 
Aptamers in the Literature 
Aptamers as therapeutic or diagnostic agents in 
cancer have been recently reviewed (Khan and 
Missailidis, 2008; Makwana et al., 2008) as has 
the potential of aptamers as radiopharmaceuticals 
in the diagnostic imaging and targeted 
radiotherapy (Perkins and Missailidis, 2007; 
Missailidis and Perkins, 2007; Ferreira and 
Missailidis, 2007). Yet, references to aptamers in 
radiotherapy or as radiopharmaceuticals have been 
sporadic at best and the field is clearly lacking in 
development. To evaluate the current state of 
research in the field of aptamers, alone and in 
relationship to cancer, therapy, diagnosis, imaging, 
radiotherapy and radiopharmaceuticals over the 
past 18 years, since the first aptamer paper 
appeared, we have used two of the largest 
scientific databases, PubMed and Web of Science, 
with some interesting results.  
The searches were performed in PubMed 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi) 
and the Web of Science in the period 1990 to 2008 
using the words: (i) aptamer*, (ii) aptamer* and 
therapy, (iii) aptamer* and diagnosis, (iv) aptamer* and 
cancer, (v) aptamer* and imaging, (vi) aptamer* and 
radiopharmaceuticals, (vii) aptamer* and radiotherapy. 
The data were obtained on August 14th, 2008.  
Our analysis of the scientific literature on aptamers 
since 1990, has been very interesting (see Table 
1). First of all, we note that, although the first 
papers on aptamers appeared almost 
simultaneously in 1990 by two independent 
groups, led by Gold and Ellington respectively 
(Tuerk and Gold, 1990; Ellington and Szostak, 
1990), there is no reference on aptamers appearing 
on either database till 1992. This, however, may be 
related to the term ‘aptamer’ not being coined and 
used widely until later on. Furthermore, although 
PubMed appears to be more widely accessible, 
Web of Science presented consistently a larger 
number of hits on aptamers and additional keywords 
we searched for, with exception to diagnosis.  
Another interesting point identified was that, 
although cancer is currently one of the most 
researched scientific areas, only 12% (according to 
PubMed) and ~8.3% (according to the Web of 
Science) of publications on aptamers are related to 
cancer. This clearly indicates that aptamers have 
found wider applications in other areas of 
research, with only limited attention to their great 
potential in cancer. Furthermore, few papers are 
related to aptamers and radiopharmaceuticals or 
aptamers and radiotherapy.  
 
Table 1 - Papers in PubMed (white) and Web of Science (gray) from 1990 to August 2008.  
Year Aptamer* 
 
Aptamer* 
and 
Diagnosis 
Aptamer* 
and 
Therapy 
Aptamer* 
and 
Cancer 
Aptamer* 
and 
imaging 
Aptamer* and 
Radio-
pharmaceuticals 
Aptamer* 
and 
Radiotherapy 
1990 - - - - - - - - - - - - - - 
1991 - - - - - - - - - - - - - - 
1992 1 1 1 - - - - - - - - - - - 
1993 12 18 1 - 2 3 - - - - - - - - 
1994 12 24 1 - 2 3 1 - - - - - - - 
1995 18 37 3 - 5 9 1 - 1 2 1 - - - 
1996 31 48 - 1 5 4 5 - - - - - - - 
1997 56 85 3 2 6 8 9 - 2 2 - 1 - - 
1998 59 86 3 - 6 2 3 1 - 1 - 1 - - 
1999 59 105 8 1 6 9 6 1 2 10 1 1 - - 
2000 91 133 13 3 12 29 7 2 2 5 - - - - 
2001 81 117 9 5 8 15 13 9 - 3 - - - - 
2002 107 157 13 6 24 34 14 14 3 11 1 1 2 2 
2003 122 207 23 11 26 50 17 13 4 12 2 3 1 3 
2004 157 243 20 9 28 49 13 17 6 15 - 1 1 1 
2005 214 305 35 12 53 70 21 26 6 14 - 1 1 1 
2006 319 413 65 24 100 115 45 55 10 20 2 4 1 5 
2007 354 484 93 36 102 130 43 51 13 32 3 4 3 4 
2008 208  404  42  30 46 61 35 47 10 19 - 0 - 1 
Total 1901 2867 333 140 431 591 227 236 59 146 10 17 9 17 
 
These are spread throughout the years, with one or 
two papers each year, with the exception of 2007 
that saw an increase to 4 papers. Yet, as 3 out of 4 
papers are reviews, there seem to be only limited 
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research on this field, with only one research paper 
this year. Given the success of aptamers in disease 
diagnosis and therapy, their radiolabelling 
potential remains an unexplored field. 
 
Aptamer Design 
High affinity and specificity aptamers are, 
primarily, generated via an in vitro selection 
process referred to as SELEX. However, recently, 
alternative selection processes have also been 
developed (Drabovich et al., 2005; Berezovski et 
al., 2005). The basic SELEX protocol is an 
evolutionary, iterant stringent process involving a 
combinatorial library of randomized nucleic acid 
sequences, with structural variations of more than 
1015 different molecules, flanked by primers that 
allow PCR amplification. This is subjected to the 
selected molecular target for a series of events of 
binding, partitioning of unbound aptamers from 
the bound, followed by elution and amplification 
of the bound aptamers, which are subsequently 
further subjected to the target. This process is 
repeated for several rounds, typically from 8 to 12, 
to obtain, through competitive binding, one or few 
aptamer sequences with high specificity and 
affinity to the chosen target. Selected aptamers are 
cloned and sequenced, to reveal the binding 
sequences. Many alterations can be made to the 
SELEX protocol, such as on the approach 
employed to present the target or the manner in 
which the aptamer-target complexes are 
partitioned. Alterations in the presentation of the 
target can entail a method of counter selection or 
ToggleSELEX, whereas variations in partitioning 
include photocrosslinking and capillary 
electrophoresis (CE) reviewed by Hamula et al. 
(2006). 
 
Chemistry and Labelling 
Oligonucleotides can now be purchased with a 
number of modifications from various providers of 
customised oligonucleotides. Such modifications 
can facilitate the interaction of aptamers with 
moieties of interest in labelling and to improve 
their pharmacokinetic properties. Thus, an amino 
modification at the aptamer terminus (either 3’ or 
5’) can facilitate the interaction of the aptamer 
with a chelator. Ideally, however, this interaction 
would be post-labelling of the chelator with a 
metal (Fig. 1), to avoid losing radioactivity, which, 
for a metal like technetium-99m that has a 6hr half 
life, is a particularly important trait.  
 
Improving Pharmacokinetic Properties 
Two major disadvantages have plagued aptamers 
since their initial development stage. The first 
major obstacle has been the degradation of 
oligonucleotides by nucleases. However, this issue 
has been resolved by a number of techniques. First 
of all, DNA aptamers have been shown to be far 
more resistant to nuclease degradation than their 
RNA counterparts. Second, modifications at the 3’ 
and/or 5’ end of the aptamer can secure nuclease 
resistance and increase the half-life of the 
molecule from minutes to hours (Khan and 
Missailidis, 2008; Makwana et al., 2008). One 
such easy modification we have used on the design 
of an aptamer radiopharmaceutical has been an 
inverted base on the unlabelled end of the aptamer 
(Borbas et al., 2007).  
The second issue is aptamers’ pharmacokinetic 
properties. Aptamers are reasonably small 
(~10kDa), hydrophilic molecules that are easily 
cleared by the kidneys. Whilst this is interesting 
for diagnostic applications, where the aptamer 
radiopharmaceutical is cleared from the system 
rapidly, decreasing any background signal, it is 
devastating for therapy, where 90% of the aptamer 
can wash out in the first 15min. Thus, pegylation 
of the aptamer on one end with radiolabelling on 
the other can quickly and confidently increase the 
half life of the molecule in serum, whilst 
conferring nuclease resistance. PEG molecules of 
various molecular weights have been used with 
aptamers, but only one with a radiolabelled 
aptamer (Hicke et al., 2006). 
 
Aptamer Radiopharmaceuticals Concluding 
Remarks 
Aptamers have a great potential in the disease 
diagnosis and therapy. They have the ability to 
bind their targets with unrivalled affinity and 
specificity, they have shown no side effects in 
treatments they have already been used, such as 
the nucleolin or the VEGF aptamer, they have no 
immunogenicity and, in the case of cancer, great 
tumour penetration (Borbas et al., 2007). 
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Figure 1 - Post-labelling of an aptamer with a chelator of interest. 
 
 
Furthermore, through labelling and PEGylation 
has the possibility to act as diagnostic, imaging or 
therapeutic agents. A few years ago, an agreement 
between a major aptamer company and the NCI 
had been reached to develop and test aptamers 
against all major known tumour markers. Yet, to 
this date, only about 10% of papers on aptamers 
are related to cancer and only a handful on 
radiopharmaceuticals. What is particularly 
interesting, however, is that although there appear 
to be 2000-3000 papers, the World Intellectual 
Property Organisation indicates 138 patents in 
PCT with the world aptamer on the front page, but 
3606 patents when searched for aptamer in ´all 
fields´ and 7671 hits on aptamer are found in Free 
Patents Online 
(http://www.freepatentsonline.com/). This is 
consistent with the great commercial interest of 
aptamers. Research publications on aptamers as 
radiopharmaceuticals remain limited and, resulting 
mostly from research of our group and 
collaborators worldwide. 
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RESUMO 
 
Na contínua busca do diagnóstico precoce e 
melhores modalidades terapêuticas contra o 
câncer, com base no constante aumento do 
conhecimento da biologia do câncer, aptâmeros 
têm a promessa de expandir o atual sucesso dos 
anticorpos, e superar alguns dos problemas 
enfrentados com os anticorpos, como agentes 
terapêuticos ou como agentes que chegam ao 
processo neoplásico. Entretanto, como o primeiro 
aptâmero chegou ao mercado como um inibidor da 
angiogênese para o tratamento da degeneração 
macular, aptâmeros tem encontrado apenas 
aplicações ou interesse limitados em oncologia, e 
ainda menos como radiofármacos para o 
diagnóstico por imagem e radioterapia direcionada 
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para tumores. A química para a marcação de 
aptâmeros e as opções para alterar suas 
propriedades radiofarmacocinéticas, para torná-los 
mais adequados para uso como radiofármacos, é 
agora disponível e os avanços recentes no seu 
desenvolvimento podem demonstrar que essas 
moléculas poderiam ser ideais como veículos para 
o desenvolvimento de radiofármacos sítio-
dirigidos que poderiam levar radiação com 
precisão para o tumor, oferecendo melhores 
propriedades terapêuticas e reduzidos efeitos 
indesejados. 
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